JC virus

Results: 46



#Item
11Biology / Infectious diseases / Progressive multifocal leukoencephalopathy / JC virus / Blood–brain barrier / AIDS / HIV / Antiretroviral drug / Opportunistic infection / Health / Medicine / HIV/AIDS

AIDS InfoNet[removed]www.aidsinfonet.org Fact Sheet Number 516 PROGRESSIVE MULTIFOCAL LEUCOENCEPHALOPATHY (PML)

Add to Reading List

Source URL: www.aidsinfonet.org

Language: English - Date: 2014-04-16 16:06:46
12Objective is to derive the over all incidence/ prevalence of PML in the USA JCV/PML Reasons for unknown incidence *Not reported

Objective is to derive the over all incidence/ prevalence of PML in the USA JCV/PML Reasons for unknown incidence *Not reported

Add to Reading List

Source URL: patients.aan.com

Language: English - Date: 2009-11-10 12:34:40
13HIGHLIGHTS OF PRESCRIBING INFORMATION  --------------------------------Contraindications-----------------------------­ These highlights do not include all the information needed to use ADCETRIS safely and effectively. S

HIGHLIGHTS OF PRESCRIBING INFORMATION --------------------------------Contraindications-----------------------------­ These highlights do not include all the information needed to use ADCETRIS safely and effectively. S

Add to Reading List

Source URL: www.accessdata.fda.gov

Language: English - Date: 2014-11-25 08:40:02
14What’s “hot” about thermogenic agents

What’s “hot” about thermogenic agents

Add to Reading List

Source URL: dpic.org

Language: English - Date: 2014-11-10 15:46:29
15060602_europa_map_80grau_jc

060602_europa_map_80grau_jc

Add to Reading List

Source URL: ecdc.europa.eu

Language: English - Date: 2014-12-22 10:31:56
16060602_europa_map_80grau_jc

060602_europa_map_80grau_jc

Add to Reading List

Source URL: www.ecdc.europa.eu

Language: English - Date: 2014-12-22 10:31:56
17Initial REMS Approval: June[removed]BLA[removed]NULOJIX (belatacept) Selective T-cell costimulation blocker Bristol-Myers Squibb (BMS) Company

Initial REMS Approval: June[removed]BLA[removed]NULOJIX (belatacept) Selective T-cell costimulation blocker Bristol-Myers Squibb (BMS) Company

Add to Reading List

Source URL: www.fda.gov

Language: English
18RAPTIVA® [efalizumab] For injection, subcutaneous WARNING: RISK OF PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY (PML) •	 RAPTIVA increases the risk for PML, a rapidly progressive viral infection of

RAPTIVA® [efalizumab] For injection, subcutaneous WARNING: RISK OF PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY (PML) • RAPTIVA increases the risk for PML, a rapidly progressive viral infection of

Add to Reading List

Source URL: www.accessdata.fda.gov

Language: English - Date: 2009-03-31 14:51:38
19Possible mechanisms of the disease

Possible mechanisms of the disease

Add to Reading List

Source URL: www.fda.gov

Language: English
20RAPTIVA® [efalizumab] For injection, subcutaneous WARNING: RISK OF PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY (PML) •	 RAPTIVA increases the risk for PML, a rapidly progressive viral infection of

RAPTIVA® [efalizumab] For injection, subcutaneous WARNING: RISK OF PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY (PML) • RAPTIVA increases the risk for PML, a rapidly progressive viral infection of

Add to Reading List

Source URL: www.fda.gov

Language: English